Sökresultat - Portal för medicinska datamodeller (MDM-portal)

Filtrera sökresultat
Välj datamodell

Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

494 Sökresultat.

dbGaP phs000388 IPM BioBank GWAS - pht002351.v1.p1

- 2022-10-12 - 4 Formulär, 1 Item-grupp, 2 Dataelement, 1 Språk

Item-grupp: pht002351

Principal Investigator: Erwin P. Bottinger, Charles R. Bronfman Institute for Personalized Medicine, Mount Sinai School of Medicine, New York, NY, USA MeSH: Coronary Artery Disease,Chronic Kidney Failure,Diabetes Mellitus, Type 2,Hypertension,Dyslipidemias https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000388 The Institute for Personalized Medicine (IPM) Biobank Project is a consented, EMR-linked medical care setting biorepository of the Mount Sinai Medical Center (MSMC) drawing from a population of over 70,000 inpatients and 800,000 outpatient visits annually. MSMC serves diverse local communities of upper Manhattan, including Central Harlem (86% African American), East Harlem (88% Hispanic Latino), and Upper East Side (88% Caucasian/white) with broad health disparities. IPM Biobank populations include 28% African American (AA), 38% Hispanic Latino (HL) predominantly of Caribbean origin, 23% Caucasian/White (CW). IPM Biobank disease burden is reflective of health disparities with broad public health impact: average body mass index of 28.9 and frequencies of hypertension (55%), hypercholesterolemia (32%), diabetes (30%), coronary artery disease (25%), chronic kidney disease (23%), among others. Biobank operations are fully integrated in clinical care processes, including direct recruitment from clinical sites, waiting areas and phlebotomy stations by dedicated Biobank recruiters independent of clinical care providers, prior to or following a clinician standard of care visit. Recruitment currently occurs at a broad spectrum of over 30 clinical care sites. Minorities are strikingly underrepresented in GWAS, including Coronary Artery Disease (CAD) and Chronic Kidney Disease; multigenic genetic risk scores for CAD have been recently validated in European ancestry populations, but not in AA or HL populations. Several important opportunities exist for extending additional GWAS to minority populations with a shared risk spectrum of CAD and CKD. For example, progressive CKD is a major and independent risk factor for CVD with an inverse relationship between estimated GFR (eGFR), and risk for mortality and cardiovascular events. This increased risk is only partially explained by the prevalence of cardiovascular risk factors among these patients. We conducted a GWAS of CAD and CKD related phenotypes in IPM Biobank with the primary objective to explore the genetics of overlapping CAD and CKD predominantly in minority populations characterized by increased risk.

pht002352.v1.p1

1 Item-grupp 2 Dataelement

pht002353.v1.p1

1 Item-grupp 9 Dataelement

Eligibility

1 Item-grupp 1 Dataelement

dbGaP phs000397 NIA Long Life Family Study (LLFS) - Eligibility

- 2022-10-12 - 6 Formulär, 1 Item-grupp, 3 Dataelement, 1 Språk

Item-grupp: IG.elig

Principal Investigator: Michael A. Province, PhD, Washington University School of Medicine, St. Louis, MO, USA MeSH: Longevity,Aging,Cardiovascular Diseases,Neoplasms,Stroke,Inflammation,Immune System,Diabetes Mellitus,Hypertension,Dyslipidemias,Lipids,Osteoporosis,Pulmonary Function Tests,Kidney Function Tests,Alzheimer Disease,Depression,Personality,Executive Function,Reproductive History https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000397 The Long Life Family Study (LLFS) is an international collaborative study of the genetics and familial components of exceptional survival, longevity, and healthy aging. Families were recruited through elderly probands (generally in their 90s) who self-reported on the survival history of their parents and siblings, and on the basis of this information, families which showed clustering of exceptional survival were recruited. [Specifically, a Family Longevity Selection Score (FLOSS) ≥7 was required. The FLOSS measures the average excess Observed lifespan over that Expected based upon lifetables, while adding a bonus term for still-living individuals. Thus FLOSS is a useful tool for scoring and selecting families for inclusion in a research study of exceptional survival (Sebastiani et al., 2009, PMID: 19910380)]. Probands resided in the catchment areas of four Field Centers (Boston University, Columbia University, University of Pittsburgh, and University of Southern Denmark). Recruited family members were phenotyped through extensive in-home visits by teams of technicians who traveled all over the USA and Denmark. Blood assays were centrally processed at a Laboratory Core (University of Minnesota) and protocols were standardized, monitored and coordinated through a Data Management Coordinating Center (Washington University). We examined and extensively phenotyped in all major domains of healthy aging, 4,953 individuals in 539 families through comprehensive in-home visits. Of these, 4,815 gave dbGaP sharing permission and had sufficient quantity/quality of DNA for GWAS genotyping. This large collection of families, selected on the basis of clustering for exceptional survival, is a unique resource for the study of human longevity and healthy aging. We estimate that less than 1% of the Framingham Heart Study (FHS) families (a roughly random population family sample) would meet the minimal entrance criteria for exceptional survival required in the LLFS (Sebastiani et al., 2009, PMID: 19910380). Thus, the least exceptional LLFS families show more clustering for exceptional longevity than 99% of the FHS families. Although the LLFS pedigrees were selected on the basis of longevity per se in the upper generation (and the generation above that), the children's generation have significantly lower rates of many major diseases and have better healthy aging profiles for many disease phenotypes (Newman et al., 2011, PMID: 21258136). The participants had their first in-person visit between 2006 and 2009. After that visit, they were contacted annually by telephone to update vital status, medical history, and general health. Between 2014 and 2017, willing participants completed a second in-person visit. The second visit followed the same protocols and centralized training as the first visit. During the second visit, a portable carotid ultrasound exam was added. Again, participants were continuously contacted annually for telephone follow-up during the period of the second in-person visit and after that. Annual telephone follow-ups currently ongoing, and plans for a third in-person visit are in progress.

pht002407.v3.p3

1 Item-grupp 4 Dataelement

pht002408.v3.p3

1 Item-grupp 6 Dataelement

pht002410.v3.p3

1 Item-grupp 106 Dataelement

pht003356.v3.p3

1 Item-grupp 4 Dataelement

pht002409.v3.p3

1 Item-grupp 3 Dataelement

Eligibility Adults With Uncontrolled Hypertension NCT01632943

- 2021-11-17 - 1 Formulär, 2 Item-grupper, 23 Dataelement, 1 Språk

Item-grupper: Inclusion Criteria, Exclusion Criteria

Single-arm Study of Symplicity™ Renal Denervation System in Patients With Uncontrolled HyperTensioN in India; ODM derived from: https://clinicaltrials.gov/show/NCT01632943

Eligibility Hypertension NCT01431508

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 23 Dataelement, 1 Språk

Item-grupper: Inclusion Criteria, Exclusion Criteria

A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3); ODM derived from: https://clinicaltrials.gov/show/NCT01431508

Eligibility Hypertension NCT01145391

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 12 Dataelement, 1 Språk

Item-grupper: Inclusion Criteria, Exclusion Criteria

Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Trial; ODM derived from: https://clinicaltrials.gov/show/NCT01145391

Eligibility Hypertension NCT01079494

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 9 Dataelement, 1 Språk

Item-grupper: Inclusion Criteria, Exclusion Criteria

Clinical Pharmacists Role in the Management of Hypertension in Jordan; ODM derived from: https://clinicaltrials.gov/show/NCT01079494

Eligibility Hypertension NCT01167920

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 15 Dataelement, 1 Språk

Item-grupper: Inclusion Criteria, Exclusion Criteria

Virtual Hypertension Clinic; ODM derived from: https://clinicaltrials.gov/show/NCT01167920

Eligibility Hypertension NCT00803634

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 19 Dataelement, 1 Språk

Item-grupper: Inclusion Criteria, Exclusion Criteria

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO); ODM derived from: https://clinicaltrials.gov/show/NCT00803634

Eligibility Hypertension NCT01038895

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 13 Dataelement, 1 Språk

Item-grupper: Inclusion Criteria, Exclusion Criteria

Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria; ODM derived from: https://clinicaltrials.gov/show/NCT01038895

Eligibility Hypertension NCT00549536

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 18 Dataelement, 1 Språk

Item-grupper: Inclusion Criteria, Exclusion Criteria

The Effect of Calcium Supplementation on Insulin Resistance and 24h Blood Pressure; ODM derived from: https://clinicaltrials.gov/show/NCT00549536

Eligibility Hypertension NCT00446511

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 11 Dataelement, 1 Språk

Item-grupper: Inclusion Criteria, Exclusion Criteria

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT00446511

Eligibility Hypertension NCT00435162

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 16 Dataelement, 1 Språk

Item-grupper: Inclusion Criteria, Exclusion Criteria

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure; ODM derived from: https://clinicaltrials.gov/show/NCT00435162

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.